Bureau of Competition: Role and Functions
The Bureau of Competition is the Federal Trade Commission division responsible for enforcing federal antitrust law and reviewing mergers and acquisitions that may harm competitive markets. Operating alongside the FTC's Bureau of Consumer Protection and Bureau of Economics, it forms one of the three principal enforcement pillars of the agency. The Bureau's work directly affects industries ranging from pharmaceuticals and technology to energy and healthcare, making it a central institution in shaping how competitive markets function across the U.S. economy.
Definition and scope
The Bureau of Competition carries statutory authority derived primarily from Section 7 of the Clayton Act (15 U.S.C. § 18), which prohibits mergers and acquisitions whose effect may be to substantially lessen competition, and from Section 5 of the FTC Act (15 U.S.C. § 45), which bars unfair methods of competition. The Bureau does not operate as a standalone enforcement body; every significant action it recommends must be approved by the full Commission, which consists of up to 5 presidentially appointed commissioners confirmed by the Senate.
Its jurisdictional scope covers the full range of FTC antitrust enforcement, including:
- Premerger notification review under the Hart-Scott-Rodino (HSR) Act
- Challenging consummated mergers that harm competition
- Investigating anticompetitive conduct such as price-fixing, bid-rigging, and exclusive dealing
- Reviewing potentially anticompetitive agreements between competitors
- Coordinating with the Department of Justice Antitrust Division on jurisdictional matters
The Bureau does not handle criminal antitrust prosecution — that authority rests exclusively with the Department of Justice Antitrust Division. The FTC's authority is civil only, meaning it pursues injunctions, divestitures, and consent orders rather than criminal penalties.
How it works
The Bureau's operational workflow follows a structured investigative and enforcement process. A typical competition matter moves through the following stages:
- Intake and screening — Staff economists and attorneys evaluate transactions or conduct reports, often triggered by HSR filings or third-party complaints. The FTC and DOJ divide review responsibility based on each agency's historical expertise in a given industry sector.
- Preliminary investigation — Staff may issue Civil Investigative Demands (CIDs) compelling the production of documents, written responses, or oral testimony from parties and third parties.
- Second Request — In merger reviews, if the initial 30-day HSR waiting period raises concerns, the Bureau may issue a Second Request, which extends the waiting period and demands a substantially larger document and data production.
- Commission vote — Bureau staff present findings and a recommended course of action. The full Commission votes on whether to authorize a complaint, accept a consent order, or close the investigation.
- Litigation or settlement — If the Commission votes to challenge a transaction or conduct, the Bureau litigates in federal district court or through FTC administrative litigation. Matters may resolve through consent orders and decrees requiring divestitures, behavioral remedies, or both.
The Bureau works closely with economists in the Bureau of Economics at every stage; no major merger recommendation proceeds without a parallel economic analysis assessing market concentration, competitive effects, and efficiencies. The FTC merger review process page details the procedural mechanics of that review in full.
Common scenarios
The Bureau's enforcement activity clusters around three recurring categories of competitive harm.
Horizontal mergers — Transactions combining direct competitors in the same product and geographic market. The 2010 Horizontal Merger Guidelines (DOJ/FTC), updated in 2023 under revised Merger Guidelines, set the analytical framework used to assess whether a proposed merger would lead to unilateral or coordinated effects that substantially lessen competition.
Pharmaceutical pay-for-delay agreements — Branded drug manufacturers paying generic competitors to delay market entry, a practice the FTC has challenged under Section 5 as an unfair method of competition. The FTC's ongoing focus on pharma and healthcare enforcement reflects the Bureau's sustained attention to this market.
Big technology acquisitions — Acquisitions in digital platform markets where network effects and data advantages may entrench dominant firms. The Bureau has pursued actions against major platform companies; FTC big tech antitrust actions catalogues notable proceedings in this space.
Naked horizontal restraints — Price-fixing or market allocation agreements between competitors, which the Bureau treats as per se violations requiring no market analysis to establish illegality.
Decision boundaries
The Bureau of Competition operates within analytical distinctions that determine how a matter is assessed and what standard of proof applies.
Per se vs. rule of reason — Certain conduct categories (price-fixing, bid-rigging, output restrictions among competitors) are per se illegal, meaning no competitive justification can save them. Other conduct — such as exclusive dealing arrangements, vertical restraints, or joint ventures — is evaluated under the rule of reason, which requires weighing anticompetitive harms against procompetitive efficiencies.
Structural vs. behavioral remedies — In merger matters, the Bureau strongly prefers structural remedies (divestitures of overlapping assets or business units) over behavioral remedies (conduct restrictions). This preference reflects the agency's view, documented in its publicly available policy statements, that behavioral remedies are difficult to monitor and enforce over time.
HSR-reportable vs. non-HSR transactions — In 2023, the FTC and DOJ raised the HSR filing threshold to $111.4 million (FTC HSR Threshold Notice), meaning transactions below that value do not require premerger notification, though they remain subject to post-consummation challenge. The premerger notification and HSR Act page covers the filing mechanics in detail.
The Bureau distinguishes its mandate sharply from that of the Bureau of Consumer Protection: the competition bureau focuses on market structure and competitor conduct, while consumer protection focuses on deceptive or unfair acts toward individual consumers. Both bureaus draw on the same enabling statute — the FTC Act — but address different categories of harm. A full overview of the FTC's scope and functional divisions is available at the FTC authority index.